Bill targets petitions used to delay generic and biosimilar drugs
In committeeH.R. 8908Latest action
Sponsor: Eric Sorensen · Representative · IL
AIDecoded by AI · checked against the recordRead the official text
Official title: STOP GAMES Act of 2026
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
The STOP GAMES Act lets the FDA quickly reject petitions filed mainly to delay generic or biosimilar drug approvals.
40-second read · 4 questions answered below
What does this do?
This bill gives the FDA clearer authority to quickly deny petitions that appear filed mainly to delay approval of competing generic or biosimilar drugs. It lists warning signs of delay tactics, shortens the petition filing deadline to 60 days, requires referrals of suspected bad-faith filers to the FTC, and tightens court rules requiring people to first go through the FDA's petition process before suing.
Who does it affect?
This mainly affects pharmaceutical and biotechnology companies, particularly brand-name drug makers who file these petitions and generic or biosimilar manufacturers seeking approval. It could indirectly affect consumers and patients who buy prescription drugs.
Why does it matter?
The changes could reduce brand-name companies' ability to delay competition through petitions, while adding stricter deadlines and procedural requirements for anyone challenging FDA drug decisions.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedMay 19, 2026
- House committeeYou are here · May 19, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the House Committee on Energy and Commerce.